Ribet 2007.

Methods	Open‐label, randomised controlled parallel‐group trial across multiple centres. Intention‐to‐treat analysis not stated
Participants	Inclusion criteria: infants with mild‐to‐moderate scalp seborrhoeic dermatitis, minimum severity score ≥ 12 (mean score in included infants = 21.8) Exclusion criteria: severity score < 12 Number of participants randomised: total not reported; "124 included infants"; intervention group 63; comparison group 61. Number of dropouts: not reported Sex: 72 boys; 52 girls Mean age: 4.2 months; range: not reported Location: France
Interventions	Treatment (n = 63) Parents applied gel containing lactamide MEA (a lactic acid ingredient commonly found in hair conditioners) followed by a shampoo, once daily for 1 week, then 2–3 times a week. Comparator (n = 61) Daily shampoo only
Outcomes	Primary outcome measures Standardised global score of area and scale on 4 zones of scalp. Secondary outcome measures Ratings of erythema Report of signs of discomfort Tolerance of the gel Assessment of outcomes performed at baseline, and on days 7, 21, and 42. No difference in measured baseline characteristics. No specific adverse effects noted. No reporting of quality of life outcomes. No mention of loss to follow‐up.
Notes	Details based on reading of the abstract only. Attempts to contact the authors unsuccessful. Most study authors were employees of a pharmaceutical laboratory that produces cradle cap products. No commercial support identified in the published abstract.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information on randomisation.
Allocation concealment (selection bias)	Unclear risk	Not stated how allocation was performed.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open‐label study.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information (no full paper available).
Selective reporting (reporting bias)	Unclear risk	Insufficient information (no full paper available).
Other bias	High risk	Research conducted in a commercial pharmaceutical laboratory that manufactured the product being tested (Pierre Fabre Research Institute). Attempts made to contact the authors to obtain further information unsuccessful.